文献速递产科母胎医学

中孕期子宫动脉多普勒用于早产型子痫前期高风险妊娠停用阿司匹林:StopPRE 试验的事后分析

Mid-trimester uterine artery Doppler for aspirin discontinuation in pregnancies at high risk for preterm pre-eclampsia: Post-hoc analysis of StopPRE trial.
PubMed 文献 · BJOG · 2023-08-09

该研究为 StopPRE 临床试验的事后分析,纳入西班牙九家产科医院中孕早期高风险、24-28 周子宫动脉搏动指数≤90 百分位的孕妇,随机分为继续每日阿司匹林 150 mg 至 36 周组与停药组。停药组早产型子痫前期发生 3/409(0.7%),继续组 5/395(1.3%),差值 -0.53(95%CI -1.91 至 0.85),符合非劣效界值 1.9%。结论认为 24-28 周停药对预防早产型子痫前期非劣于继续用药至 36 周。

要点

  • 24-28 周子宫动脉搏动指数≤90 百分位的高风险孕妇,停用阿司匹林对早产型子痫前期非劣于继续用至 36 周。
  • 停药组早产型子痫前期 0.7%(3/409),继续组 1.3%(5/395),差值 -0.53(95%CI -1.91 至 0.85)。
  • 非劣效界值设为早产型子痫前期发生率差值 1.9%。

核心结论

  • 在 24-28 周子宫动脉搏动指数≤90 百分位的高风险孕妇中,停用阿司匹林对预防早产型子痫前期非劣于继续用药至 36 周。

研究设计与样本

  • StopPRE 临床试验的事后分析,西班牙九家产科医院参与,2019 年 9 月至 2021 年 9 月。
  • 孕 11-13 周子痫前期高风险且 24-28 周子宫动脉多普勒正常者,每日阿司匹林 150 mg,按 1:1 随机分为继续用药至 36 周组或停药组。
  • 本次分析排除 24-28 周子宫动脉搏动指数>90 百分位者,1611 例合格者中排除 139 例,最终纳入 804 例。

主要发现

  • 停药组早产型子痫前期 3/409(0.7%),继续组 5/395(1.3%),差值 -0.53(95%CI -1.91 至 0.85)。
  • 非劣效界值设为早产型子痫前期发生率差值 1.9%,结果提示停药非劣于继续用药。

关键数值与推荐

  • 停药组早产型子痫前期 3/409(0.7%)vs 继续组 5/395(1.3%),差值 -0.53(95%CI -1.91 至 0.85)。
  • 非劣效界值为早产型子痫前期发生率差值 1.9%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess whether aspirin treatment can be discontinued in pregnancies with normal uterine artery pulsatility index (≤90th percentile) at 24-28 weeks. DESIGN: Post-hoc analysis of a clinical trial. SETTING: Nine maternity hospitals in Spain. POPULATION OR SAMPLE: Pregnant individuals at high risk of pre-eclampsia at 11-13 weeks and normal uterine artery Doppler at 24-28 weeks. METHODS: All participants received treatment with daily aspirin at a dose of 150 mg. Participants were randomly assigned, in a 1:1 ratio, either to continue aspirin treatment until 36 weeks (control group) or to discontinue aspirin treatment (intervention group), between September 2019 and September 2021. In this secondary analysis, women with a UtAPI >90th percentile at 24-28 weeks were excluded. The non-inferiority margin was set at a difference of 1.9% for the incidence of preterm pre-eclampsia. MAIN OUTCOME MEASURES: Incidence of preterm pre-eclampsia. RESULTS: Of the 1611 eligible women, 139 were excluded for UtAPI >90th percentile or if UtAPI was not available. Finally, 804 were included in this post-hoc analysis. Preterm pre-eclampsia occurred in three of 409 (0.7%) women in the aspirin discontinuation group and five of 395 (1.3%) women in the continuation group (-0.53; 95% CI -1.91 to 0.85), indicating non-inferiority of aspirin discontinuation. CONCLUSIONS: Discontinuing aspirin treatment at 24-28 weeks in women with a UtAPI ≤90th percentile was non-inferior to continuing aspirin treatment until 36 weeks for preventing preterm pre-eclampsia.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Bonacina E, Garcia-Manau P, López M, et al. Mid-trimester uterine artery Doppler for aspirin discontinuation in pregnancies at high risk for preterm pre-eclampsia: Post-hoc analysis of StopPRE trial. BJOG. 2023. PMID: 37555464. doi:10.1111/1471-0528.17631

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。